{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T03:33:54Z","timestamp":1648697634177},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T00:00:00Z","timestamp":1336521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00059-012-3619-8","type":"journal-article","created":{"date-parts":[[2012,5,7]],"date-time":"2012-05-07T10:19:10Z","timestamp":1336385950000},"page":"384-394","source":"Crossref","is-referenced-by-count":0,"title":["Rolle der neuen oralen Antikoagulanzien im Vergleich zu Vitamin-K-Antagonisten in der Praxis"],"prefix":"10.1007","volume":"37","author":[{"given":"A.","family":"Osterspey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Krome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,9]]},"reference":[{"key":"3619_CR1","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"European","year":"2010","unstructured":"European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchof P, Lip GHJ et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369\u20132429","journal-title":"Eur Heart J"},{"key":"3619_CR2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","volume":"366","author":"Healey","year":"2012","unstructured":"Healey JS, Conolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120\u2013129","journal-title":"N Engl J Med"},{"key":"3619_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-2008-1038216","volume":"76","author":"Reicke","year":"2008","unstructured":"Reicke B, Masuhr F, Weih M (2008) Analyse des \u201eNichtgebrauchs\u201c der oralen Antikoagulation zur Schlaganfallpr\u00e4vention bei Vorhofflimmern: Eine prospektive Studie. Fortschr Neurol Psychiat 76:391\u2013395","journal-title":"Fortschr Neurol Psychiat"},{"key":"3619_CR4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al; RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"3619_CR5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al; ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"3619_CR6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al; ROCKET AF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"3619_CR7","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","volume":"365","author":"Budnitz","year":"2011","unstructured":"Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002\u20132012","journal-title":"N Engl J Med"},{"key":"3619_CR8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857\u2013867","journal-title":"Ann Intern Med"},{"key":"3619_CR9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C et al; AVERROES Steering Committee and Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806\u2013817","journal-title":"N Engl J Med"},{"key":"3619_CR10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/01.STR.0000198839.61112.ee","volume":"37","author":"Sato","year":"2006","unstructured":"Sato H, Ishikawa K, Kitabatake A et al; Japan Atrial Fibrillation Stroke Trial Group (2006) Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 37(2):447\u2013451","journal-title":"Stroke"},{"key":"3619_CR11","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","volume":"360","author":"ACTIVE","year":"2009","unstructured":"ACTIVE Investigators, Conolly S, Pogue J, Hart RG et al (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360:2066\u20132078","journal-title":"N Engl J Med"},{"key":"3619_CR12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"ACTIVE","year":"2006","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators, Conolly S, Pogue J, Hart R et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903\u20131912","journal-title":"Lancet"},{"key":"3619_CR13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","volume":"374","author":"Holmes","year":"2009","unstructured":"Holmes DR, Reddy VY, Turi ZG et al; PROTECT AF Investigators (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:534\u2013542","journal-title":"Lancet"},{"key":"3619_CR14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJMe1109748","volume":"365","author":"Mega","year":"2011","unstructured":"Mega JL (2011) A new era for anticoagulation in atrial fibrillation. N Engl J Med 365:1052\u20131054","journal-title":"N Engl J Med"},{"key":"3619_CR15","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","volume":"365","author":"Goldhaber","year":"2011","unstructured":"Goldhaber SZ, Leizorovicz A, Kakkar AK et al; ADOPT Trial Investigators (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167\u20132177","journal-title":"N Engl J Med"},{"key":"3619_CR16","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"Lassen","year":"2010","unstructured":"Lassen MR, Gallus A, Raskob GE et al; ADVANCE-3 Investigators (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487\u20132498","journal-title":"N Engl J Med"},{"key":"3619_CR17","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","volume":"5","author":"Lassen","year":"2007","unstructured":"Lassen MR, Davidson BL, Gallus A (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368\u20132375","journal-title":"J Thromb Haemost"},{"key":"3619_CR18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365(8):699\u2013708","journal-title":"N Engl J Med"},{"key":"3619_CR19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949\u2013956","journal-title":"Lancet"},{"key":"3619_CR20","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178\u20132185","journal-title":"J Thromb Haemost"},{"key":"3619_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0883-5403(08)00955-8","volume":"24","author":"Ginsberg","year":"2009","unstructured":"Ginsberg JS, Davidson BL, Comp PC et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1\u20139","journal-title":"J Arthroplasty"},{"key":"3619_CR22","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al; RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342\u20132352","journal-title":"N Engl J Med"},{"key":"3619_CR23","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ et al; RECORD1 Study Group (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765\u20132775","journal-title":"N Engl J Med"},{"key":"3619_CR24","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC et al; RECORD3 Investigators (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776\u20132786","journal-title":"N Engl J Med"},{"key":"3619_CR25","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"EINSTEIN","year":"2010","unstructured":"EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499\u20132510","journal-title":"N Engl J Med"},{"key":"3619_CR26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erc.11.62","volume":"9","author":"Romualdi","year":"2011","unstructured":"Romualdi E, Donadini MP, Ageno W (2011) Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study). Expert Rev Cardiovasc Ther 9:841\u2013844","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"3619_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD et al; ATLAS ACS 2\u2013TIMI 51 Investigators (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9\u201319","journal-title":"N Engl J Med"},{"key":"3619_CR28","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/eurheartj\/ehr344","volume":"32","author":"Hohnloser","year":"2011","unstructured":"Hohnloser S, Connolly SJ (2011) Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. Eur Heart J 32:2347\u20132349","journal-title":"Eur Heart J"},{"key":"3619_CR29","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","volume":"32","author":"Fox","year":"2011","unstructured":"Fox KA, Piccini JP, Wojdyla D et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32(19):2387\u20132394","journal-title":"Eur Heart J"},{"key":"3619_CR30","doi-asserted-by":"crossref","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation Online 2011\/06\/09, Circulation 124(14):1573\u20131579","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"3619_CR31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00108-010-2725-z","volume":"51","author":"V\u00f6ller","year":"2010","unstructured":"V\u00f6ller H, Alban S, Westermann D (2010) Neue orale Antikoagulanzien: Werden sie die Vitamin-K-Antagonisten verdr\u00e4ngen? Internist 51:1571\u20131581","journal-title":"Internist"},{"key":"3619_CR32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","volume":"125","author":"Hohnloser","year":"2012","unstructured":"Hohnloser SH, Oldgren J, Yang S et al (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125(5):669\u2013676","journal-title":"Circulation"},{"key":"3619_CR33","first-page":"A2544","volume":"108","author":"Osterspey","year":"2011","unstructured":"Osterspey A, Zylka-Menhorn V (2011) Neue orale Antikoagulantien: Sehr potent, aber kostspielig. Dtsch Arztebl 108(47):A2544\u20132546","journal-title":"Dtsch Arztebl"},{"key":"3619_CR34","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1161\/CIRCULATIONAHA.107.187998","volume":"117","author":"Rosamond","year":"2008","unstructured":"Rosamond W, Flegal K, Furie K et al (2008) Heart disease and stroke statistics \u2013 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25\u2013e146","journal-title":"Circulation"},{"key":"3619_CR35","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/01.STR.0000217450.21310.90","volume":"37","author":"Kolominsky-Rabas","year":"2006","unstructured":"Kolominsky-Rabas PL, Heuschmann PU, Marschall D et al (2006) Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 37:1179\u20131183","journal-title":"Stroke"},{"key":"3619_CR36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/hrt.2002.008748","volume":"90","author":"Stewart","year":"2004","unstructured":"Stewart S, Murphy N, Walker A et al (2004) Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 90:286\u2013292","journal-title":"Heart"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-012-3619-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-012-3619-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-012-3619-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:56:34Z","timestamp":1558540594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-012-3619-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,9]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["3619"],"URL":"https:\/\/doi.org\/10.1007\/s00059-012-3619-8","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,9]]}}}